肾移植中Luminex阳性而流式细胞术阴性的系统评价与荟萃分析
该系统评价与荟萃分析纳入7项回顾性研究,比较Luminex阳性而流式细胞术交叉配型阴性(PLNF)的肾移植受者与DSA阴性受者的预后。
要点
- PLNF移植与DSA阴性移植相比,1年急性排斥发生率无显著差异(RR=1.35,95%CI 0.90-2.02,P=0.14)。
- 1年和5年移植物失功及患者死亡率在两组间均无显著差异,异质性多较低。
- 现有证据提示单独Luminex检测的低水平DSA在中短期内不构成显著风险,避免PLNF移植可能缺乏依据。
核心结论
- 当前证据表明,单独Luminex检测的低水平DSA至少在中短期内不构成显著风险。
- 考虑到供肾短缺和等待时间延长,避免PLNF移植可能缺乏依据,尤其对长期等待患者。
主要发现
- 1年急性排斥发生率无显著差异(RR=1.35,95%CI 0.90-2.02,Z=1.46,P=0.14,I2=0%)。
- 1年移植物失功无显著差异(RR=1.66,95%CI 0.94-2.94,Z=1.75,P=0.08,I2=23%)。
- 5年移植物失功无显著差异(RR=1.29,95%CI 0.90-1.87,Z=1.38,P=0.17,I2=0%)。
- 1年患者死亡率无显著差异(RR=0.89,95%CI 0.31-2.56,Z=0.22,P=0.82,I2=0%)。
- 5年患者死亡率无显著差异(RR=1.76,95%CI 0.48-6.48,Z=0.85,P=0.39,I2=61%)。
关键数值与推荐
- 1年急性排斥:RR=1.35,95%CI 0.90-2.02,P=0.14。
- 1年移植物失功:RR=1.66,95%CI 0.94-2.94,P=0.08。
- 5年移植物失功:RR=1.29,95%CI 0.90-1.87,P=0.17。
- 1年患者死亡率:RR=0.89,95%CI 0.31-2.56,P=0.82。
- 5年患者死亡率:RR=1.76,95%CI 0.48-6.48,P=0.39。
临床怎么用
- 对于单独Luminex检测低水平DSA且流式细胞术交叉配型阴性的肾移植候选者,中短期风险与DSA阴性者相当。
- 在供肾短缺和等待时间长的背景下,对此类患者避免移植可能并非必要,尤其长期等待者。
局限性
- 纳入研究均为回顾性,可能存在偏倚。
- 移植物功能因数据不足未能进行汇总分析。
- 5年患者死亡率分析异质性较高(I2=61%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The presence of pre-formed donor-specific antibodies (DSAs) in kidney transplantation is associated with worse overall outcomes compared with DSA-negative transplantation. A positive complement-dependant cytotoxic crossmatch presents a high immunological risk, while a negative flow cytometry crossmatch is at the lower end of the risk spectrum. Yet, the presence of low-level DSA detected by Luminex alone, that is, positive Luminex and negative flow (PLNF) cytometry crossmatch lacks robust scientific exploration. In this systematic review and pooled analysis, we investigate the glomerular filtration rate, acute rejection (AR), graft survival and patient survival of PLNF transplants compared with DSA-negative transplants. Our analysis identified seven retrospective studies consisting of 429 PLNF transplants and 10 677 DSA-negative transplants. Pooled analysis identified no significant difference in the incidence of AR at 1 year [relative risk (RR) = 1.35, 95% confidence interval (CI) 0.90-2.02, Z = 1.46, P = 0.14, I2 = 0%], graft failure at 1 year (RR = 1.66, 95% CI 0.94-2.94, Z = 1.75, P = 0.08, I2 = 23%), graft failure at 5 years (RR = 1.29, 95% CI 0.90-1.87, Z = 1.38, P = 0.17, I2 = 0%), patient mortality at 1 year (RR = 0.89, 95% CI 0.31-2.56, Z = 0.22, P = 0.82, I2 = 0%) and patient mortality at 5 years (RR = 1.76, 95% CI 0.48-6.48, Z = 0.85, P = 0.39, I2 = 61%). Pooled analysis of graft function was not possible due to insufficient data. Current evidence suggests that low-level DSA detected by Luminex alone does not pose significant risk at least in the short-medium term. Considering the shortage of kidney transplants and the ever-increasing waiting time, the avoidance of PLNF transplants may be unwarranted especially in patients who have been enlisted for a long time.
引用
- Buttigieg J, Ali H, Sharma A, et al. Positive Luminex and negative flow cytometry in kidney transplantation: a systematic review and meta-analysis. Nephrol Dial Transplant. 2019. PMID: 30508114. doi:10.1093/ndt/gfy349
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。